Therefore, in patients receiving dasatinib, coadministration of a potent CYP3A4 inhibitor is not recommended (see section 4.5).
Seetõttu ei ole dasatiniibi kasutavatel patsientidel tugeva CYP3A4 inhibiitori samaaegne kasutamine soovitatav (vt lõik 4. 5).